Progress of treatment strategy in atrial fibrillation with non-structural heart disease

doi:10.3969/j.issn.1004-583X.2016.01.008

Abstract

Abstract: Atrial fibrillation (AF) is one of the most common cardiac arrhythmias. Based on the symptom and duration, AF can be clinically classified into five types: first detected, paroxysmal, persistent, long-standing persistent and permanent AF. According to the haemodynamic condition and duration, rhythm-control strategy (conversion and maintenance of sinus rhythm), rate-control strategy and continuous anticoagulation strategy are optional. Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists (VKAs). The status of catheter ablation improves gradually, especially for the paroxysmal AF with non-structural heart disease, and now catheter ablation has been considered as a first line treatment and may be prior to anti-arrhythmic drug therapy in symptomatic paroxysmal AF with non-structural heart disease.

Key words: atrial fibrillation, anticoagulants

CLC Number:

R541.75

Ding Chao. Progress of treatment strategy in atrial fibrillation with non-structural heart disease[J]. Clinical Focus, 2016, 31(1): 30-33.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.008

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/30

References

[1] European Heart Rhythm Association.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2010,31(19):2369-2429.
[2] Patel NJ, Deshmukh A, Pant S.Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning[J]. Circulation,2014,129(23):2371-2379.
[3] 黄从新,马长生,杨延宗,等.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志, 2006,10(3):167-190.
[4] Singh S, Zoble RG, Yellen L.Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study[J]. Circulation,2000,102(19):2385-2390.
[5] Singh BN, Singh SN, Reda DJ.Amiodarone versus sotalol for atrial fibrillation[J]. N Engl J Med,2005,352(18):1861-1872.
[6] Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study[J]. Arch Intern Med,2005,165(10):1185-1191.
[7] 凌兰.338例急诊就诊心房颤动患者临床分析[D].北京:中国协和医科大学, 2009.
[8] Lip GY, Halperin JL, Tse HF. The 2010 European Society of Cardiology Guidelines on the management of atrial fibrillation: an evolution or revolution[J].Chest,2011,139(4):738-741.
[9] Olesen JB, Fauchier L, Lane DA, Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project[J]. Chest,2012,141(1):147-153.
[10] 徐荣,郭金成,郭明.老年心房颤动患者华法林长期抗凝治疗的效果与安全性[J]. 临床荟萃,2015,30(3):272-275.
[11] Banerjee A, Clementy N, Haguenoer K. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project[J].Am J Med,2014,127(10):972-978.
[12] Connolly S, Pogue J, Hart R. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial[J]. Lancet, 2006,367(9526):1903-1912.
[13] Connolly SJ, Ezekowitz MD, Yusuf S. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2009,361(12):1139-1151.
[14] Patel MR, Mahaffey KW, Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10): 1557-1559.
[15] Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2011,365(11):981-992.
[16] Calkins H, Kuck KH, Cappato R. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design[J]. Europace,2012,14(4):528-606.
[17] Deshmukh A, Patel NJ, Pant S. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures[J]. Circulation,2013,128(19):2104-2112.
[18] Park JW, Leithuser B, Gerk U. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes[J]. J Invasive Cardiol,2009,21(9):446-450.